Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein.

Calabresi L, Franceschini G.

Curr Opin Lipidol. 1997 Aug;8(4):219-24. Review.

PMID:
9253538
2.

Genetic determinants of low high-density lipoprotein cholesterol.

Miller M, Zhan M.

Curr Opin Cardiol. 2004 Jul;19(4):380-4. Review.

PMID:
15218400
3.

Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease.

Vega GL, Grundy SM.

Curr Opin Lipidol. 1996 Aug;7(4):209-16. Review.

PMID:
8883496
4.

High density lipoprotein, apolipoprotein A-I, and coronary artery disease.

Srivastava RA, Srivastava N.

Mol Cell Biochem. 2000 Jun;209(1-2):131-44. Review.

PMID:
10942211
5.

High density lipoproteins and coronary heart disease. Future prospects in gene therapy.

Fruchart JC, Duriez P.

Biochimie. 1998 Feb;80(2):167-72. Review.

PMID:
9587674
6.
7.

ApoA-I(MALLORCA) impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia.

Martín-Campos JM, Julve J, Escolà JC, Ordóñez-Llanos J, Gómez J, Binimelis J, González-Sastre F, Blanco-Vaca F.

J Lipid Res. 2002 Jan;43(1):115-23.

8.

Gene-drug interaction: additive influence of mutant APOA1 and testosterone on plasma HDL-cholesterol.

Keyhan G, Rosset J, Wang J, Miller D, McManus R, Hegele RA.

Clin Biochem. 2002 Jul;35(5):341-6.

PMID:
12270762
9.

A novel mutant, ApoA-I nichinan (Glu235-->0), is associated with low HDL cholesterol levels and decreased cholesterol efflux from cells.

Han H, Sasaki J, Matsunaga A, Hakamata H, Huang W, Ageta M, Taguchi T, Koga T, Kugi M, Horiuchi S, Arakawa K.

Arterioscler Thromb Vasc Biol. 1999 Jun;19(6):1447-55.

10.
11.
12.

Genetic polymorphisms and mutations of the lipoprotein lipase gene in Japanese schoolchildren with hypoalphalipoproteinemia.

Yamana K, Yanagi H, Hirano C, Kobayashi K, Tanaka M, Tomura S, Tsuchiya S, Hamaguchi H.

J Atheroscler Thromb. 1998;4(3):97-101.

PMID:
9730139
14.

Apolipoprotein A-IFIN (Leu159-->Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts.

Miettinen HE, Jauhiainen M, Gylling H, Ehnholm S, Palomäki A, Miettinen TA, Kontula K.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3021-32.

15.

Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice.

Christoffersen C, Jauhiainen M, Moser M, Porse B, Ehnholm C, Boesl M, Dahlbäck B, Nielsen LB.

J Biol Chem. 2008 Jan 25;283(4):1839-47. Epub 2007 Nov 15.

16.

Correction of hypoalphalipoproteinemia in LDL receptor-deficient rabbits by lecithin:cholesterol acyltransferase.

Brousseau ME, Wang J, Demosky SJ Jr, Vaisman BL, Talley GD, Santamarina-Fojo S, Brewer HB Jr, Hoeg JM.

J Lipid Res. 1998 Aug;39(8):1558-67.

17.
18.

Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men.

Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE, Humphries SE.

Ann Hum Genet. 2002 Mar;66(Pt 2):111-24.

19.

Common genetic variants that relate to disorders of lipid transport in Spanish subjects with premature coronary artery disease.

Masana L, Febrer G, Cavanna J, Baroni MG, Marz W, Hoffmann MM, Shine B, Galton DJ.

Clin Sci (Lond). 2001 Feb;100(2):183-90.

PMID:
11171287

Supplemental Content

Support Center